

# Reisa A Sperling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7916145/publications.pdf>

Version: 2024-02-01

458  
papers

51,073  
citations

4658  
85  
h-index

1715  
213  
g-index

594  
all docs

594  
docs citations

594  
times ranked

35282  
citing authors

#	ARTICLE	IF	CITATIONS
1	Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 169-180.	0.8	11
2	Plasma IL-12/IFN- $\gamma$ axis predicts cognitive trajectories in cognitively unimpaired older adults. <i>Alzheimer's and Dementia</i> , 2022, 18, 645-653.	0.8	39
3	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97
4	Variant-dependent heterogeneity in amyloid $\beta$ burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. <i>Lancet Neurology</i> , The, 2022, 21, 140-152.	10.2	34
5	Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI. <i>Neurology</i> , 2022, 98, .	1.1	10
6	Racial and socioeconomic status differences in stress, posttraumatic growth, and mental health in an older adult cohort during the COVID-19 pandemic. <i>EClinicalMedicine</i> , 2022, 45, 101343.	7.1	21
7	Lower novelty-related locus coeruleus function is associated with $\beta$ -related cognitive decline in clinically healthy individuals. <i>Nature Communications</i> , 2022, 13, 1571.	12.8	32
8	Association of Emerging $\beta$ -Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults. <i>Neurology</i> , 2022, 98, .	1.1	20
9	Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid- $\beta$ and Tau Pathology in Middle-Aged Adults: The Framingham Study. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1371-1383.	2.6	18
10	Amyloid- $\beta$ and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2113641119.	7.1	26
11	Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 54.	6.2	24
12	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 592.	9.0	29
13	Associations Between Brainstem Volume and Alzheimer's Disease Pathology in Middle-Aged Individuals of the Framingham Heart Study. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1603-1609.	2.6	0
14	Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults. <i>Neurology</i> , 2022, 98, .	1.1	7
15	Association of $\beta$ -Amyloid and Vascular Risk on Longitudinal Patterns of Brain Atrophy. <i>Neurology</i> , 2022, 99, .	1.1	8
16	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 426-438.	1.8	30
17	Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. <i>Neurology</i> , 2021, 96, e619-e631.	1.1	45
18	Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 27.	6.2	34

#	ARTICLE	IF	CITATIONS
19	Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12199.	2.4	14
20	Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults. <i>Neurology</i> , 2021, 96, e1844-e1854.	1.1	38
21	Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study. <i>Neurology</i> , 2021, 96, e1491-e1500.	1.1	52
22	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 813-821.	0.8	8
23	Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 293.	9.0	57
24	The impact of COVID-19 on the well-being and cognition of older adults living in the United States and Latin America. <i>EClinicalMedicine</i> , 2021, 35, 100848.	7.1	22
25	KL <sup>+</sup> -VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE <sup>ε</sup> -4 carriers. <i>Neurobiology of Aging</i> , 2021, 101, 123-129.	3.1	10
26	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. <i>NeuroImage</i> , 2021, 231, 117845.	4.2	38
27	Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. <i>Neurology</i> , 2021, 96, .	1.1	18
28	Stress, resilience, and coping strategies in a sample of community-dwelling older adults during COVID-19. <i>Journal of Psychiatric Research</i> , 2021, 138, 176-185.	3.1	53
29	Association of cortical microstructure with amyloid- $\beta^2$ and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. <i>Molecular Psychiatry</i> , 2021, 26, 7813-7822.	7.9	17
30	Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's™s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies. <i>SLEEP Advances</i> , 2021, 2, zpab015.	0.2	9
31	In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's™s disease pathology and cognitive decline. <i>Science Translational Medicine</i> , 2021, 13, eabj2511.	12.4	107
32	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. <i>Nature Reviews Neurology</i> , 2021, 17, 703-714.	10.1	65
33	Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12135.	3.7	11
34	The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's™s disease assessed with positron emission tomography. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	111
35	Development and Validation of a Deep Learning Model for Earlier Detection of Cognitive Decline From Clinical Notes in Electronic Health Records. <i>JAMA Network Open</i> , 2021, 4, e2135174.	5.9	8
36	Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer's™s Disease Biomarkers and Mood Symptoms. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 806432.	3.4	7

#	ARTICLE	IF	CITATIONS
37	AHEAD 3â€45 study: Preliminary screening and baseline characteristics from a placeboâ€controlled, doubleâ€blind study evaluating lecanemab in participants with preclinical Alzheimerâ€™s disease and elevated (A45 trial) and intermediate (A3 trial) amyloid. Alzheimer's and Dementia, 2021, 17, .	0.8	1
38	Brainstem volume is negatively associated with amyloid deposition in the Framingham Heart Study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
39	Cortical microstructure is associated with tau burden and predicts cognitive decline and clinical progression in healthy older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0
40	Trajectories of selfâ€rated concerns in individuals developing cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.8	0
41	CSF polygenic risk AD biomarkers predict brain amyloid and free recall. Alzheimer's and Dementia, 2021, 17, .	0.8	1
42	Associations between biomarker status (amyloid, tau) and risk for progression to MCI/Dementia in the Harvard Aging Brain Study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
43	Locus coeruleus integrity as a proxy of initial tau burden: in vivo versus ex vivo observations. Alzheimer's and Dementia, 2021, 17, .	0.8	0
44	Amyloidâ€ <sup>12</sup> and tau pathologies relate to distinctive brain dysconnectomics in autosomalâ€dominant Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	2
45	Extraneous neuroimaging factors do not contribute to sex differences in flortaucipir signal: Analysis of skull binding and partial volume effects. Alzheimer's and Dementia, 2021, 17, .	0.8	1
46	Associations between remote cognitive testing on an individualâ€™s own digital device and amyloid burden on neuroimaging in clinically normal older adults: Results from Boston Remote Assessment for Neurocognitive Health (BRANCH). Alzheimer's and Dementia, 2021, 17, .	0.8	1
47	Greater psychological resilience during the COVIDâ€19 pandemic is associated with lower tau burden in cognitively unimpaired individuals. Alzheimer's and Dementia, 2021, 17, .	0.8	0
48	Reduced amyloid and greater neuropsychological testing exclusion in the A4 study in individuals that selfâ€identify as nonâ€Hispanic Asian. Alzheimer's and Dementia, 2021, 17, .	0.8	1
49	Sequential early cognitive changes sensitive to rising betaâ€amyloid and tau pathology in preclinical AD. Alzheimer's and Dementia, 2021, 17, .	0.8	0
50	Cognition and hippocampal volume in amyloid positive clinically normal adults: Results from the A4 study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
51	Longitudinal associations between amyloid and tauâ€PET: Impact for prevention trials. Alzheimer's and Dementia, 2021, 17, .	0.8	0
52	Associations between plasma pâ€tau <sub>217</sub> , in vivo brain pathology and cognition in individuals with autosomalâ€dominant Alzheimerâ€™s disease: Findings from the Colombiaâ€Boston (COLBOS) biomarker study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
53	Selfâ€reported history of estrogen hormone therapy differentiates rates of amyloid accumulation (PiBâ€PET) relative to males: Findings from the Harvard Aging Brain Study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
54	Amygdala tau pathology in preclinical autosomal dominant Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
55	The combined influence of beta-amyloid and vascular risk on prospective brain atrophy in clinically normal individuals. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
56	The impact of COVID-19 on the well-being and cognition of older adults living in the United States and Latin America. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
57	Longitudinal trajectories of remote assessment of self- and study partner-rated cognitive concerns, mood and Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
58	Monthly computerized at-home assessments to detect cognitive change in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
59	Regional beta-amyloid and tau deposition: Results from the Framingham Heart Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
60	Resilience and perceived stress in cognitively normal older adults during the COVID-19 pandemic. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
61	Multimodal neuroimaging biomarkers of Alzheimer's disease in older adults with depression: Preliminary findings from a pilot cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
62	The location of <i>PSEN1</i> pathogenic variants in transmembrane vs. cytoplasmic domains may alter neurodegenerative and cognitive trajectories: Findings from the DIAN study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
63	Menopause moderates sex differences in tau PET signal: Findings from the Framingham Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
64	Locus coeruleus integrity predicts tau accumulation and memory dysfunction in autosomal dominant Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e052664.	0.8	0
65	Sex differences in the genetic architecture underlying resilience in AD.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e055010.	0.8	0
66	Cell type-specific Alzheimer's disease polygenic risk scores are associated with distinct disease processes in preclinical Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e055304.	0.8	0
67	Sex-specific genetic predictors of memory performance.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e056083.	0.8	0
68	Association of anxiety with subcortical amyloidosis in cognitively normal older adults. <i>Molecular Psychiatry</i> , 2020, 25, 2599-2607.	7.9	28
69	Longitudinal degradation of the default/salience network axis in symptomatic individuals with elevated amyloid burden.. <i>NeuroImage: Clinical</i> , 2020, 26, 102052.	2.7	18
70	Functional and Pathological Correlates of Judgments of Learning in Cognitively Unimpaired Older Adults. <i>Cerebral Cortex</i> , 2020, 30, 1974-1983.	2.9	7
71	Cerebral amyloid angiopathy and Alzheimer disease – one peptide, two pathways. <i>Nature Reviews Neurology</i> , 2020, 16, 30-42.	10.1	407
72	Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. <i>Alzheimer's and Dementia</i> , 2020, 16, 552-560.	0.8	55

#	ARTICLE	IF	CITATIONS
73	Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 330-332.	1.9	7
74	Resting-state functional connectivity and amyloid burden influence longitudinal cortical thinning in the default mode network in preclinical Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102407.	2.7	23
75	Multiple markers contribute to risk of progression from normal to mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2020, 28, 102400.	2.7	8
76	Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. <i>Nature Communications</i> , 2020, 11, 6024.	12.8	43
77	Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. <i>JAMA Neurology</i> , 2020, 77, 1504.	9.0	48
78	The neurophysiology and seizure outcomes of late onset unexplained epilepsy. <i>Clinical Neurophysiology</i> , 2020, 131, 2667-2672.	1.5	9
79	The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 104.	6.2	7
80	Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 99.	6.2	22
81	Tracking the origin of tau spread in the brain. <i>Alzheimer's and Dementia</i> , 2020, 16, e037501.	0.8	0
82	Repeated memory-based assessments: Implications for clinical trials and practice. <i>Alzheimer's and Dementia</i> , 2020, 16, e038143.	0.8	1
83	Association of tau tangle burden with depressive symptoms in community-dwelling older adults: A longitudinal study. <i>Alzheimer's and Dementia</i> , 2020, 16, e038867.	0.8	0
84	Sex, tau, and cortical thinning in the temporal lobe: Findings from the Harvard Aging Brain Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e040031.	0.8	0
85	The dynamic interplay between longitudinal subjective and objective cognitive decline along the early AD spectrum in the Harvard Aging Brain Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e040260.	0.8	0
86	Hypoconnectivity between locus coeruleus and medial temporal lobe during novelty predicts accelerated A $\beta$ -related cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e041323.	0.8	2
87	Evaluating pre-screening tools for older Latino recruitment into preclinical Alzheimer's disease studies. <i>Alzheimer's and Dementia</i> , 2020, 16, e041571.	0.8	0
88	The relationship between cortical microstructural changes and in vivo amyloid $\beta$ and tau in aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041626.	0.8	0
89	Genetic associations with brain amyloidosis. <i>Alzheimer's and Dementia</i> , 2020, 16, e042191.	0.8	0
90	The anti-amyloid treatment in asymptomatic Alzheimer's disease (A4) study: Report of screening and recruitment characteristics of the Melbourne composite site. <i>Alzheimer's and Dementia</i> , 2020, 16, e042786.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Sex differences in genetic predictors of resilience to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043259.	0.8	0
92	Longitudinal inferior temporal PET signal increase is associated with contemporaneous longitudinal temporal lobe cortical thinning in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043419.	0.8	0
93	Estimating an individual's placement on a theoretical continuum using longitudinal cognitive trajectories: Relationships with longitudinal amyloid and Tau PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e043566.	0.8	0
94	Faster rates of tau accumulation in PET in females relative to males, and a cross-sectional influence on faster cognitive decline: Preliminary findings from HABS and ADNI. <i>Alzheimer's and Dementia</i> , 2020, 16, e043620.	0.8	0
95	Associations of peak width of skeletonized mean diffusivity with cardiovascular disease risk and cognitive decline in clinically normal older adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e043812.	0.8	0
96	Vascular risk and physical activity as modulators of cognitive and neurodegenerative trajectories: Independent and interactive effects with beta-amyloid. <i>Alzheimer's and Dementia</i> , 2020, 16, e044145.	0.8	0
97	Are amyloid and tau synergistic? How to interpret an amyloid/tau interaction on cognitive decline in clinically normal adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e044310.	0.8	0
98	AHEAD 3-45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer's disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial). <i>Alzheimer's and Dementia</i> , 2020, 16, e044511.	0.8	14
99	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044787.	0.8	1
100	Study partner factors on cognitive function index scores among participants screened for the A4 study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044871.	0.8	0
101	Alternatives to MMRM for preclinical Alzheimer's clinical trials. <i>Alzheimer's and Dementia</i> , 2020, 16, e044915.	0.8	0
102	Plasma levels of an N-terminal tau fragment are highly associated with future cognitive decline and neurodegeneration in clinically normal elderly. <i>Alzheimer's and Dementia</i> , 2020, 16, e045261.	0.8	0
103	Initial exploration of a brain age score based on validated computerized cognitive assessments in Japanese individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, e045446.	0.8	1
104	Plasma IL-12/IFN- $\gamma$ axis predicts cognitive trajectories in cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e045497.	0.8	0
105	Longitudinal hippocampal atrophy is associated with an amyloid-independent entorhinal tauopathy and an amyloid-dependent neocortical tauopathy. <i>Alzheimer's and Dementia</i> , 2020, 16, e045733.	0.8	1
106	Multimodal genome-wide meta-analysis of brain amyloidosis reveals heterogeneity across CSF, PET, and pathological amyloid measures. <i>Alzheimer's and Dementia</i> , 2020, 16, e046009.	0.8	0
107	Distinct contributions of longitudinal tau and amyloid to decline in various cognitive domains in preclinical AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e046075.	0.8	0
108	Dementia knowledge and associated demographic factors within a registry sample. <i>Alzheimer's and Dementia</i> , 2020, 16, e046177.	0.8	1



#	ARTICLE	IF	CITATIONS
109	Surface-based amyloid and tau correlates of digital clock drawing performance. <i>Alzheimer's and Dementia</i> , 2020, 16, e046461.	0.8	0
110	Depressive symptoms are associated with hippocampal neurodegeneration in preclinical autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046495.	0.8	0
111	Association of tau tangle burden with depressive symptoms in community-dwelling older adults: A longitudinal study. <i>Alzheimer's and Dementia</i> , 2020, 16, e046549.	0.8	0
112	Longitudinal increase in depressive symptoms in relation to neurodegeneration in clinically normal older adults: Findings from the Harvard Aging Brain Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e047321.	0.8	0
113	Harmonizing the preclinical Alzheimer cognitive composite for multi-cohort studies. <i>Alzheimer's and Dementia</i> , 2020, 16, e047423.	0.8	2
114	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 138.	6.2	14
115	Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1437-1446.	2.6	18
116	Association Between Common Variants in <i>RBFox1</i> , an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 1288.	9.0	41
117	The presubiculum links incipient amyloid and tau pathology to memory function in older persons. <i>Neurology</i> , 2020, 94, e1916-e1928.	1.1	13
118	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 142, 104960.	4.4	31
119	Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults. <i>NeuroImage</i> , 2020, 220, 116991.	4.2	31
120	Genetics of Gene Expression in the Aging Human Brain Reveal TDP-43 Proteinopathy Pathophysiology. <i>Neuron</i> , 2020, 107, 496-508.e6.	8.1	29
121	Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. <i>Neurology</i> , 2020, 95, e1312-e1321.	1.1	7
122	Associations of Widowhood and $\beta$ -Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults. <i>JAMA Network Open</i> , 2020, 3, e200121.	5.9	27
123	Word retrieval across the biomarker-confirmed Alzheimer's disease syndromic spectrum. <i>Neuropsychologia</i> , 2020, 140, 107391.	1.6	17
124	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. <i>JAMA Neurology</i> , 2020, 77, 735.	9.0	182
125	Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults. <i>Neurobiology of Aging</i> , 2020, 93, 124-130.	3.1	27
126	The A4 study: $\beta$ -Amyloid and cognition in 4432 cognitively unimpaired adults. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 776-785.	3.7	43



#	ARTICLE	IF	CITATIONS
127	The impact of amyloidâ€beta and tau on prospective cognitive decline in older individuals. <i>Annals of Neurology</i> , 2019, 85, 181-193.	5.3	171
128	Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. <i>JAMA Network Open</i> , 2019, 2, e198964.	5.9	72
129	Associations of Physical Activity and $\beta$ -Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. <i>JAMA Neurology</i> , 2019, 76, 1203.	9.0	97
130	Amyloid imaging of dutchâ€type hereditary cerebral amyloid angiopathy carriers. <i>Annals of Neurology</i> , 2019, 86, 616-625.	5.3	22
131	â€Alzheimer's diseaseâ€ is neither â€Alzheimer's clinical syndromeâ€ nor â€dementiaâ€. <i>Alzheimer's and Dementia</i> , 2019, 15, 153-157.	0.8	23
132	Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimerâ€™s Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 757-768.	2.6	32
133	Polygenic hazard score, amyloid deposition and Alzheimerâ€™s neurodegeneration. <i>Brain</i> , 2019, 142, 460-470.	7.6	63
134	Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 4.	6.2	9
135	Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. <i>JAMA Neurology</i> , 2019, 76, 542.	9.0	201
136	Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 915.	9.0	512
137	Social Engagement and Amyloid- $\beta$ -Related Cognitive Decline in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 1247-1256.	1.2	56
138	Synergism between fornix microstructure and beta amyloid accelerates memory decline in clinically normal older adults. <i>Neurobiology of Aging</i> , 2019, 81, 38-46.	3.1	17
139	O300 Linking Sleep Disturbances with Amyloid and Tau Imaging. Preliminary Findings from the Harvard Aging Brain Study. <i>Sleep</i> , 2019, 42, A122-A123.	1.1	0
140	An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1161-1170.	2.6	5
141	Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2019, 78, 178-185.	3.1	54
142	Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimerâ€™s Disease. <i>New England Journal of Medicine</i> , 2019, 380, 1483-1485.	27.0	149
143	Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 14.	6.2	26
144	Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 17.	6.2	26

#	ARTICLE	IF	CITATIONS
145	P4â€496: MYELOID CELLâ€SPECIFIC ALZHEIMER'S DISEASE POLYGENIC RISK SCORE PREDICTS NEURODEGENERATION AND AÎ²â€RELATED COGNITIVE DECLINE IN COGNITIVELY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2019, 15, P1503.	0.8	0
146	ICâ€Pâ€178: SEX DIFFERENCES IN TAU PATHOLOGY ACROSS CORTICAL AND SUBCORTICAL REGIONS OF INTEREST: FINDINGS ACROSS TWO COHORTS. Alzheimer's and Dementia, 2019, 15, P139.	0.8	0
147	P4â€607: FREE AND CUED MEMORY IS DISTINCTLY RELATED TO PATHOLOGY IN PRECLINICAL AUTOSOMALâ€DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1557.	0.8	0
148	ICâ€Pâ€037: GERIATRIC DEPRESSION SCALE ITEMâ€LEVEL ANALYSIS IN RELATION TO AÎ²<i>IN VIVO</i> CORTICAL AMYLOID AND CEREBRAL REGIONAL TAU IN CLINICALLY NORMAL OLDER ADULTS: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2019, 15, P43.	0.8	0
149	ICâ€Pâ€089: ASSOCIATIONS OF REGIONAL CORTICAL THINNING AND LONGITUDINAL COGNITIVE PERFORMANCE IN THE CONTEXT OF AMYLOID IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2019, 15, P79.	0.8	0
150	F2â€03â€01: CLINICAL MEANINGFULNESS OF SHORTâ€TERM COGNITIVE DECLINE ON THE PRECLINICAL ALZHEIMER'S COGNITIVE COMPOSITEâ€5 (PACCâ€5) IN NORMAL OLDER ADULTS WITH ELEVATED Î²â€AMYLOID. Alzheimer's and Dementia, 2019, 15, P518.	0.8	0
151	ICâ€Pâ€008: ANATOMICAL STAGING OF BETAâ€AMYLOID ACCUMULATION BASED ON LONGITUDINAL ASSESSMENT OF GLOBALLY PIB NEGATIVE ADULTS. Alzheimer's and Dementia, 2019, 15, P18.	0.8	0
152	P4â€608: TAU ACCUMULATION AND VISUAL MEMORY IN COGNITIVELY UNIMPAIRED PSEN1 E280A MUTATION CARRIERS. Alzheimer's and Dementia, 2019, 15, P1557.	0.8	0
153	Resistance to autosomal dominant Alzheimerâ€™s disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 2019, 25, 1680-1683.	30.7	328
154	ICâ€Pâ€058: COVARYING SPATIAL PATTERNS OF TAU DEPOSITION AND GRAY MATTER ATROPHY UNEARTHED BY THE INFORMED MULTIMODAL PARTIAL LEAST SQUARES (MMPLS) IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: FINDINGS FROM THE COLBOS PROJECT. Alzheimer's and Dementia, 2019, 15, P58.	0.8	0
155	Dementia is not synonymous with Alzheimerâ€™s disease. Science Translational Medicine, 2019, 11, .	12.4	11
156	O3â€09â€01: PROTECTIVE EFFECT OF PHYSICAL ACTIVITY ON LONGITUDINAL COGNITIVE DECLINE AND NEURODEGENERATION IN CLINICALLY NORMAL OLDER ADULTS WITH ELEVATED Î²â€AMYLOID BURDEN. Alzheimer's and Dementia, 2019, 15, P903.	0.8	0
157	Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults. Neurolmage: Clinical, 2019, 24, 102097.	2.7	7
158	Anticholinergic Amnesia is Mediated by Alterations in Human Network Connectivity Architecture. Cerebral Cortex, 2019, 29, 3445-3456.	2.9	12
159	Vascular Risk and <b>Î²</b>â€Amyloid Are Synergistically Associated with Cortical Tau. Annals of Neurology, 2019, 85, 272-279.	5.3	75
160	Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity. Journal of Neuroscience, 2019, 39, 548-556.	3.6	75
161	Dissecting the genetic relationship between cardiovascular risk factors and Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 137, 209-226.	7.7	100
162	Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers. Neurolmage, 2019, 186, 446-454.	4.2	16

#	ARTICLE	IF	CITATIONS
163	Seizures as an early symptom of autosomal dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 18-23.	3.1	27
164	Global White Matter Diffusion Characteristics Predict Longitudinal Cognitive Change Independently of Amyloid Status in Clinically Normal Older Adults. <i>Cerebral Cortex</i> , 2019, 29, 1251-1262.	2.9	47
165	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018, 141, 1486-1500.	7.6	79
166	NIA's Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.8	5,861
167	18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1691-1702.	2.6	67
168	Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. <i>Nature Neuroscience</i> , 2018, 21, 424-431.	14.8	198
169	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. <i>Neurology</i> , 2018, 90, e877-e886.	1.1	28
170	Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 548.	9.0	137
171	The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 121-129.	2.4	11
172	Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. <i>American Journal of Psychiatry</i> , 2018, 175, 530-537.	7.2	175
173	Dissociable influences of APOE $\epsilon$ 4 and polygenic risk of AD dementia on amyloid and cognition. <i>Neurology</i> , 2018, 90, e1605-e1612.	1.1	71
174	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. <i>Alzheimer's and Dementia</i> , 2018, 14, 43-53.	0.8	42
175	Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals. <i>NeuroImage: Clinical</i> , 2018, 17, 388-396.	2.7	8
176	ICA-P41: LONGITUDINAL CHANGE OF FUNCTIONAL CONNECTIVITY IN PRECLINICAL AD: RESULTS FROM THE HARVARD AGING BRAIN STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P41.	0.8	1
177	O4-P01: COMPARISON OF THE NATURAL HISTORY OF NEOCORTICAL $\beta$ -AMYLOID, HIPPOCAMPAL VOLUME AND PACC IN SPORADIC AD. <i>Alzheimer's and Dementia</i> , 2018, 14, P1423.	0.8	0
178	O1-P03: DIGITIZED CLOCK DRAWING (DCTCLOCK <sup>TM</sup> ) PERFORMANCE AND ITS RELATIONSHIP TO AMYLOID AND TAU PET IMAGING MARKERS IN UNIMPAIRED OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P236.	0.8	1
179	O3-P12: DECREASED META-MEMORY FOR EPISODIC BUT NOT SEMANTIC INFORMATION IS ASSOCIATED WITH EARLY TAUOPATHY IN CLINICALLY NORMAL OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1050.	0.8	0
180	P1-P327: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNITIVE DECLINE IN OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P417.	0.8	0

#	ARTICLE	IF	CITATIONS
181	P3â€136: MODULE QUANTITATIVE TRAIT LOCI ANALYSIS IMPLICATES <i>TMEM106B</i> AND <i>RBFOX1</i> AS KEY BRAIN TRANSCRIPTOME REGULATORS IN OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1120.	0.8	0
182	P4â€094: OCCIPITAL TO GLOBAL PIB UPTAKE IS ASSOCIATED WITH THE PRESENCE OF MICROHEMORRHAGES AND MUTATIONS ASSOCIATED WITH CEREBRAL AMYLOID ANGIOPATHY IN THE DOMINANTLY INHERITED ALZHEIMER'S NETWORK. <i>Alzheimer's and Dementia</i> , 2018, 14, P1472.	0.8	1
183	P3â€370: AN APOEÎµ4 DERIVED STATISTICAL METHOD FOR OPTIMIZING TARGET AND REFERENCE REGIONS FOR AMYLOIDâ€PET IMAGING. <i>Alzheimer's and Dementia</i> , 2018, 14, P1231.	0.8	0
184	P3â€290: AMYLOID PATHOLOGY EXPLAINS UNAWARENESS OF MEMORY DEFICITS ABOVE AND BEYOND CORTICAL THICKNESS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1191.	0.8	0
185	O1â€02â€02: THE ANTIâ€AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMER'S DISEASE (A4) STUDY: REPORT OF SCREENING DATA RESULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P215.	0.8	3
186	O3â€04â€03: AMYLOID IS ASSOCIATED WITH GREATER TAU BURDEN IN CLINICALLY NORMAL FEMALES RELATIVE TO MALES: FINDINGS FROM TWO INDEPENDENT COHORTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1019.	0.8	0
187	O1â€02â€01: IMPACT OF DISCLOSING AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL RESEARCH PARTICIPANTS: THE A4 EXPERIENCE. <i>Alzheimer's and Dementia</i> , 2018, 14, P215.	0.8	0
188	P1â€480: LOCUS COERULEUS SIGNAL INTENSITY IS ASSOCIATED WITH ENTORHINAL TAU PATHOLOGY AT HIGHER LEVELS OF AMYLOID BURDEN. <i>Alzheimer's and Dementia</i> , 2018, 14, P509.	0.8	1
189	ICâ€Pâ€159: BRAIN RESILIENCE PROTECTS AGAINST COGNITIVE DECLINE ASSOCIATED WITH ELEVATED AMYLOID BURDEN. <i>Alzheimer's and Dementia</i> , 2018, 14, P134.	0.8	0
190	F4â€08â€02: AMYLOID BURDEN AND VASCULAR RISK ARE INDEPENDENTLY ASSOCIATED WITH SUBJECTIVE COGNITIVE DECLINE IN CLINICALLY NORMAL OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1394.	0.8	0
191	P2â€452: TAU ACCUMULATION IN RHINAL CORTEX IS ASSOCIATED WITH MEMORY PERFORMANCE IN NONDEMENTED YOUNG ADULTS WITH AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P892.	0.8	0
192	O1â€02â€05: PREDICTING AMYLOID BURDEN IN SCREENING FOR PRECLINICAL AD PREVENTION TRIALS. <i>Alzheimer's and Dementia</i> , 2018, 14, P217.	0.8	0
193	O1â€10â€03: SEX AND <i>APOE</i> GENOTYPE INFLUENCE THE ASSOCIATION BETWEEN AMYLOID AND LONGITUDINAL TAU PATHOLOGY IN CLINICALLY NORMAL OLDER ADULTS: FINDINGS FROM THE ADNI STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P243.	0.8	0
194	ICâ€Pâ€215: TAU ACCUMULATION IN RHINAL CORTEX IS ASSOCIATED WITH MEMORY PERFORMANCE IN NONâ€DEMENTED YOUNG ADULTS WITH AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P176.	0.8	0
195	ICâ€Pâ€139: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNITIVE DECLINE IN OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P116.	0.8	0
196	P4â€118: AV1451 TAU PET, BUT NOT CSF TAU, IS RELATED TO MEMORY DECLINE IN PRECLINICAL AND PRODROMAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1484.	0.8	0
197	ICâ€02â€04: REGIONAL ASYMMETRIES IN AMYLOID AND TAU GO TOGETHER: EVIDENCE FOR LOCAL INTERACTION. <i>Alzheimer's and Dementia</i> , 2018, 14, P4.	0.8	1
198	Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1409-1424.	2.6	22

#	ARTICLE	IF	CITATIONS
199	P1â€³01: CERTAIN PLASMA Nâ€³TERMINAL TAU FRAGMENTS ARE ELEVATED IN AD AND ADâ€³MCI COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P405.	0.8	0
200	ICâ€³Pâ€³140: TAU ACCUMULATION AND MEMORY DECLINE ARE MORE CLOSELY RELATED TO STRIATAL THAN CORTICAL AMYLOIDOSIS IN INDIVIDUALS WITH EARLYâ€³ONSET AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P117.	0.8	0
201	P2â€³461: ENTORHINAL TAU PATHOLOGY IS ASSOCIATED WITH WHITE MATTER ABNORMALITIES IN UNCINATE FASCICULUS IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P897.	0.8	0
202	ICâ€³Pâ€³147: QUANTIFYING STAGES OF SUBTLE MEMORY IMPAIRMENT IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P125.	0.8	1
203	Regional tau pathology and loneliness in cognitively normal older adults. Translational Psychiatry, 2018, 8, 282.	4.8	46
204	O2â€³08â€³06: AMYLOIDâ€³P, COGNITION AND SOCIAL ACTIVITY IN COGNITIVELY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P640.	0.8	0
205	Amyloidâ€³associated increases in longitudinal report of subjective cognitive complaints. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 444-449.	3.7	51
206	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.8	51
207	Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nature Medicine, 2018, 24, 1910-1918.	30.7	135
208	Dedifferentiation of caudate functional connectivity and striatal dopamine transporter density predict memory change in normal aging. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10160-10165.	7.1	49
209	Sex, amyloid, and <i>APOE</i> Îµ4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three wellâ€³characterized cohorts. Alzheimer's and Dementia, 2018, 14, 1193-1203.	0.8	169
210	Interactive Associations of Vascular Risk and Î²2-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals. JAMA Neurology, 2018, 75, 1124.	9.0	165
211	PET staging of amyloidosis using striatum. Alzheimer's and Dementia, 2018, 14, 1281-1292.	0.8	93
212	Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE Îµ4 haplotype status: a community-based cohort study. Lancet Neurology, The, 2018, 17, 773-781.	10.2	101
213	A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimerâ€³s Disease. Journal of Alzheimer's Disease, 2018, 65, 107-115.	2.6	9
214	Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimerâ€³s Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. Journal of Alzheimer's Disease, 2018, 64, 689-707.	2.6	15
215	What Happens with the Circuit in Alzheimer's Disease in Mice and Humans?. Annual Review of Neuroscience, 2018, 41, 277-297.	10.7	154
216	The Impact of Awareness of and Concern About Memory Performance on the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease Dementia. American Journal of Geriatric Psychiatry, 2018, 26, 896-904.	1.2	23

#	ARTICLE	IF	CITATIONS
217	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. PLoS ONE, 2018, 13, e0195838.	2.5	51
218	P3899: ASSOCIATION BETWEEN CORTICAL THINNING AND TAU PATHOLOGY IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1253.	0.8	0
219	Age-Related Increases in Tip-of-the-tongue are Distinct from Decreases in Remembering Names: A Functional MRI Study. Cerebral Cortex, 2017, 27, 4339-4349.	2.9	14
220	Harvard Aging Brain Study: Dataset and accessibility. NeuroImage, 2017, 144, 255-258.	4.2	107
221	Loneliness, depression and cognitive function in older U.S. adults. International Journal of Geriatric Psychiatry, 2017, 32, 564-573.	2.7	269
222	Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology, 2017, 88, 1431-1438.	1.1	46
223	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid $\beta$ . Alzheimer's and Dementia, 2017, 13, 1004-1012.	0.8	139
224	Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Annals of Neurology, 2017, 81, 583-596.	5.3	110
225	Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease. American Journal of Geriatric Psychiatry, 2017, 25, 683-693.	1.2	37
226	Neuroimaging markers associated with maintenance of optimal memory performance in late-life. Neuropsychologia, 2017, 100, 164-170.	1.6	35
227	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. Scientific Reports, 2017, 7, 1225.	3.3	42
228	Functional network integrity presages cognitive decline in preclinical Alzheimer disease. Neurology, 2017, 89, 29-37.	1.1	106
229	The association between tau PET and retrospective cortical thinning in clinically normal elderly. NeuroImage, 2017, 157, 612-622.	4.2	74
230	Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging. NeuroImage: Clinical, 2017, 15, 408-414.	2.7	61
231	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA - Journal of the American Medical Association, 2017, 317, 2305.	7.4	311
232	Tau and amyloid $\beta$ proteins distinctively associate to functional network changes in the aging brain. Alzheimer's and Dementia, 2017, 13, 1261-1269.	0.8	90
233	Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease. Neuropsychologia, 2017, 99, 343-349.	1.6	67
234	Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden. Neurology, 2017, 88, 1759-1767.	1.1	50



#	ARTICLE	IF	CITATIONS
235	Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals. <i>Journal of Neuroscience</i> , 2017, 37, 4323-4331.	3.6	237
236	The influence of demographic factors on subjective cognitive concerns and beta-amyloid. <i>International Psychogeriatrics</i> , 2017, 29, 645-652.	1.0	17
237	Cardiorespiratory fitness is differentially associated with cortical thickness in young and older adults. <i>NeuroImage</i> , 2017, 146, 1084-1092.	4.2	61
238	Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global $\beta$ -Amyloid Burden. <i>JAMA Neurology</i> , 2017, 74, 1455.	9.0	119
239	Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1451-1459.	2.6	80
240	Subjective memory complaints in preclinical autosomal dominant Alzheimer disease. <i>Neurology</i> , 2017, 89, 1464-1470.	1.1	23
241	Subjective cognitive concerns are associated with objective memory performance in Caucasian but not African-American persons. <i>Age and Ageing</i> , 2017, 46, 988-993.	1.6	44
242	[O4â€“07â€“06]: <i>IN VIVO</i> SPREADING PATHWAYS OF TAU AND AMYLOID ACCUMULATION AND ITS GENETIC UNDERPINNINGS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1246.	0.8	0
243	Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. <i>Brain Imaging and Behavior</i> , 2017, 11, 383-390.	2.1	54
244	Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , 2017, 13, 296-311.	0.8	375
245	[P3â€“376]: QRISK2 AND FRAMINGHAM CARDIOVASCULAR RISK SCORES SIGNIFICANTLY CORRELATE WITH IMAGING BIOMARKERS OF PRECLINICAL AD: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1103.	0.8	1
246	[P4â€“228]: LONGITUDINAL TAU ACCUMULATION IS ASSOCIATED WITH COGNITIVE DECLINE IN NORMAL ELDERLY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1357.	0.8	0
247	[P4â€“243]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1369.	0.8	0
248	[P1â€“154]: <i>APOE</i> $\epsilon$ 4 IS ASSOCIATED WITH HIGHER TDP $\epsilon$ 43 PROTEINOPATHY BURDEN IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P301.	0.8	0
249	[ICâ€“Pâ€“041]: SAMPLE SIZES FOR 24â€“MONTH ALZHEIMER'S PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOIDâ€“POSITIVE ADULTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P36.	0.8	0
250	[ICâ€“Pâ€“089]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P72.	0.8	0
251	[ICâ€“Pâ€“108]: ASSOCIATIONS BETWEEN MEASURES OF MEDIAL TEMPORAL LOBE NEURODEGENERATION AND ANOSOGNOSIA FOR MEMORY DEFICITS. <i>Alzheimer's and Dementia</i> , 2017, 13, P85.	0.8	0
252	[ICâ€“Pâ€“181]: LONGITUDINAL TAU ACCUMULATION IS ASSOCIATED WITH COGNITIVE DECLINE IN NORMAL ELDERLY. <i>Alzheimer's and Dementia</i> , 2017, 13, P134.	0.8	2



#	ARTICLE	IF	CITATIONS
253	[P1â€“03]: TAU AND HIPPOCAMPAL VOLUME REFLECT DISTINCT PROCESSES IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P5.	0.8	1
254	[P1â€“256]: BASELINE CARDIOVASCULAR RISK AND AMYLOID BURDEN SYNERGISTICALLY PREDICT LONGITUDINAL COGNITIVE DECLINE IN CLINICALLY NORMAL ELDERLY: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P347.	0.8	0
255	[P1â€“398]: TAU ACCUMULATION IS DETECTABLE AND CORRELATED TO AMYLOID BURDEN IN NORMAL AND IMPAIRED OLDER INDIVIDUALS USING SERIAL PET. <i>Alzheimer's and Dementia</i> , 2017, 13, P423.	0.8	0
256	[P1â€“434]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVITY IN THE DEFAULT MODE NETWORK IN AUTOSOMALâ€“DOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P448.	0.8	0
257	[P2â€“115]: A <i>TMEM106B</i> LOCUS IS IMPLICATED IN COGNITIVE DECLINE IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P650.	0.8	0
258	[P2â€“298]: ASSOCIATIONS BETWEEN MEASURES OF MEDIAL TEMPORAL LOBE NEURODEGENERATION AND ANOSOGNOSIA FOR MEMORY DEFICITS. <i>Alzheimer's and Dementia</i> , 2017, 13, P730.	0.8	0
259	[F1â€“03â€“02]: SUBJECTIVE COGNITIVE DECLINE, LONGITUDINAL COGNITIVE PERFORMANCE, AND IMAGING BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P176.	0.8	0
260	[O1â€“02â€“05]: GENOTYPIC VARIANCE MAY EXPLAIN THE BALANCE OF EARLY CORTICAL VERSUS STRIATAL AMYLOID DEPOSITION IN AUTOSOMAL DOMINANT AD. <i>Alzheimer's and Dementia</i> , 2017, 13, P187.	0.8	1
261	[O1â€“13â€“01]: SUBJECTIVE CONCERNS PREFERENTIALLY ASSOCIATE WITH AMYLOID BURDEN AND MEMORY IN CAUCASIANS, BUT WHITE MATTER HYPERINTENSITIES AND EXECUTIVE FUNCTION IN AFRICANâ€“AMERICANS. <i>Alzheimer's and Dementia</i> , 2017, 13, P225.	0.8	0
262	[O2â€“10â€“03]: SEVERITY OF SUBJECTIVE COGNITIVE DECLINE ALIGNS WITH REGIONAL AMYLOID SEVERITY: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P577.	0.8	0
263	[O2â€“11â€“04]: COGNITIVE RESERVE RELATES TO GREATER FUNCTIONAL CONNECTIVITY AND STRONGER INTERCONNECTIVITY WITHIN AND BETWEEN NODES, INDEPENDENT OF Î²â€“AMYLOID: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P582.	0.8	0
264	[F3â€“05â€“03]: OBJECTIVE AND SUBJECTIVE COGNITIVE DECLINE IN BLACK AMERICANS FROM THE HARVARD AGING BRAIN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P885.	0.8	0
265	[O3â€“06â€“02]: SEMANTIC MEMORY AND PET AMYLOID AND TAU DEPOSITION IN PRECLINICAL AND PRODROMAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P911.	0.8	0
266	[O3â€“07â€“06]: THE RELATIONSHIP BETWEEN RECALL OF RECENTLY VERSUS REMOTELY ENCODED FAMOUS FACES AND AMYLOID AND TAU BURDEN IN CLINICALLY NORMAL OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P917.	0.8	0
267	[P4â€“500]: SPATIAL PATTERNS OF FLORTAUCIPIR (FTP) SIGNAL IN COGNITIVELY NORMAL ELDERLY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1530.	0.8	1
268	[P4â€“534]: LINKING MEASURES OF SUBJECTIVE COGNITION ACROSS INTERNATIONAL AGING STUDIES USING ITEM RESPONSE THEORY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1554.	0.8	1
269	Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 668-677.	3.7	160
270	Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 975-985.	2.6	70

#	ARTICLE	IF	CITATIONS
271	Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional data. PLoS Medicine, 2017, 14, e1002287.	8.4	88
272	On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2017, 9, 60.	6.2	316
273	[P1â€“030]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVITY IN THE DEFAULT MODE NETWORK IN AUTOSOMALâ€œDOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT. 0.8 Alzheimer's and Dementia, 2017, 13, P245.	0.8	0
274	Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly. Journal of prevention of Alzheimer's disease, The, 2017, 4, 81-86.	2.7	8
275	Multiple Brain Markers are Linked to Age-Related Variation in Cognition. Cerebral Cortex, 2016, 26, 1388-1400.	2.9	146
276	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	2.5	45
277	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547.	1.1	1,216
278	Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity. Human Brain Mapping, 2016, 37, 621-631.	3.6	24
279	P3â€œ09: Profiles of Cognitive Decline Associated with Biomarkerâ€œDefined Preclinical Stages of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P960.	0.8	0
280	IC-P-063: Polygenic Risk of Alzheimer's Disease is Associated with Early and Late Life Processes. , 2016, 12, P50-P51.		11
281	Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly. Journal of Alzheimer's Disease, 2016, 53, 1097-1105.	2.6	44
282	P3-275: Increased TAU PET Signal Associated with Longitudinal Mr Atrophy in Cognitively Normal Older Adults. , 2016, 12, P940-P941.		0
283	P4-217: Regional Fluorodeoxyglucose Hypometabolism is Associated With Greater Apathy Over Time in Early Alzheimer's Disease. , 2016, 12, P1111-P1111.		0
284	F5â€œ04â€œ03: TRCâ€œPAD: Using Runâ€œIn Data for Screen Failure Reduction. Alzheimer's and Dementia, 2016, 12, P372.	0.8	1
285	F5-05-02: The Harvard Automated Phone Task (APT): A Novel Performance-Based ADL Instrument for Early Alzheimer's Disease. , 2016, 12, P373-P373.		1
286	P4-396: Using an Internet Registry to Supplement Recruitment Efforts for Clinical Research. , 2016, 12, P1189-P1189.		0
287	ICâ€œPâ€œ013: Pet Staging of Amyloidosis: Evidence that Amyloid Occurs First in Neocortex and Later in Striatum. Alzheimer's and Dementia, 2016, 12, P20.	0.8	1
288	IC-P-043: Neuroimaging Correlates of Anosognosia in Mild Cognitive Impairment. , 2016, 12, P36-P37.		1

#	ARTICLE	IF	CITATIONS
289	ICâ€Pâ€053: Regional Fluorodeoxyglucose Hypometabolism is Associated with Greater Apathy Over Time in Early Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P43.	0.8	0
290	P2-341: Subjective Cognitive Decline Predicts Longitudinal Decline in those with Both Amyloidosis and Neurodegeneration. , 2016, 12, P773-P774.		0
291	P3-322: Optimal Memory Performance in Older Adults is Associated with Differences in Hippocampal Volume and Amyloid Status at Baseline and Over 3 Years. , 2016, 12, P969-P969.		0
292	ICâ€Pâ€185: The Effect of Tractâ€Specific Loss of White Matter Connectivity on Cognitive Decline in Healthy Older Individuals Depends on Entorhinal T807 Binding. Alzheimer's and Dementia, 2016, 12, P135.	0.8	0
293	ICâ€Pâ€190: Increased TAU PET Signal Associated with Longitudinal Mr Atrophy in Cognitively Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P137.	0.8	0
294	F1â€04â€01: Longitudinal Performance on the Preclinical Alzheimerâ€™s Cognitive Composite (PACC) in Subjects with Biomarkerâ€Defined Preclinical ad. Alzheimer's and Dementia, 2016, 12, P167.	0.8	0
295	O1â€13â€01: Anxiety, Social Activity and Amyloid in Cognitively Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P208.	0.8	0
296	O2â€03â€02: are White Matter Hyperintensities a Core Feature of Alzheimerâ€™s Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2016, 12, P226.	0.8	1
297	F3-04-01: In Vivo Cortical Distribution of Tau and Amyloid Deposits in Cognitively Normal Elderly. , 2016, 12, P274-P274.		0
298	O3â€08â€03: The Effect of Tractâ€Specific Loss of White Matter Connectivity on Cognitive Decline in Healthy Older Individuals Depends on Entorhinal T807 Binding. Alzheimer's and Dementia, 2016, 12, P304.	0.8	0
299	O3â€09â€03: Associations between Amyloidosis and Longitudinal Cognitive Decline in Clinically Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P308.	0.8	0
300	F4â€03â€03: Antiâ€Amyloid Treatment of Asymptomatic Ad: A4 and Beyond. Alzheimer's and Dementia, 2016, 12, P326.	0.8	2
301	O4â€01â€02: Tau and Amyloid Pet Imaging in a Colombian Kindred with Autosomalâ€Dominant Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P330.	0.8	0
302	O4â€01â€06: Ab+ Clinically Normal Participants with Elevated Tau Show Greatest Decline in the Preclinical Alzheimerâ€™s Disease Cognitive Composite. Alzheimer's and Dementia, 2016, 12, P333.	0.8	0
303	O4-06-04: Neuroimaging Correlates of Anosognosia in Mild Cognitive Impairment. , 2016, 12, P345-P346.		0
304	O4â€06â€06: The Impact of Anosognosia and Anosodiaphoria on the Prediction of Progression from Mild Cognitive Impairment to Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P346.	0.8	1
305	O4â€07â€05: Pet Staging of Amyloidosis: Evidence that Amyloid Occurs First in Neocortex and Later in Striatum. Alzheimer's and Dementia, 2016, 12, P349.	0.8	0
306	P4-325: TAU BURDEN is Associated with Subjective Cognitive Concerns in the Context of Î²2-Amyloid Burden in Preclinical ad. , 2016, 12, P1158-P1159.		0

#	ARTICLE	IF	CITATIONS
307	P4-354: Subjective Cognitive Concerns are Associated with Objective Memory Performance in Older Caucasian but not African-American Persons. , 2016, 12, P1173-P1173.		1
308	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. Alzheimer's and Dementia, 2016, 12, 510-515.	0.8	23
309	Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease. Neurobiology of Aging, 2016, 42, 177-188.	3.1	57
310	Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study. Lancet Neurology, The, 2016, 15, 811-819.	10.2	96
311	Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. Annals of Neurology, 2016, 80, 846-857.	5.3	36
312	Research priorities to reduce the global burden of dementia by 2025. Lancet Neurology, The, 2016, 15, 1285-1294.	10.2	284
313	Decreased hippocampal metabolism in highâ€œamyloid mild cognitiveâ€œimpairment. Alzheimer's and Dementia, 2016, 12, 1288-1296.	0.8	23
314	Tau positron emission tomographic imaging in aging and early <scp>A</scp> Alzheimer disease. Annals of Neurology, 2016, 79, 110-119.	5.3	778
315	Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology, 2016, 87, 920-926.	1.1	86
316	Heterogeneity in Suspected Nonâ€œAlzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. JAMA Neurology, 2016, 73, 1185.	9.0	52
317	Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology, 2016, 87, 481-488.	1.1	159
318	In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. Journal of Neuroscience, 2016, 36, 7364-7374.	3.6	153
319	FTS2-01-05: From the who Research Priorities and Research Portfolio Analysis to the Identification of Research Gaps to Reduce the Global Burden of Dementia. , 2016, 12, P220-P220.		0
320	F4-03-01: Collaboration for Alzheimer's Prevention (CAP): Advancing the Evaluation of Preclinical Alzheimer's Disease Treatments. , 2016, 12, P325-P326.		0
321	ICâ€œPâ€œ198: TAU and Amyloid PET Imaging in a Colombian Kindred with Autosomalâ€œDominant Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P143.	0.8	0
322	Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. JAMA Psychiatry, 2016, 73, 1230.	11.0	164
323	<i>Trans</i>-pQTL study identifies immune crosstalk between Parkinson and Alzheimer loci. Neurology: Genetics, 2016, 2, e90.	1.9	31
324	Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimer's and Dementia, 2016, 12, 631-632.	0.8	26

#	ARTICLE	IF	CITATIONS
325	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. <i>Annals of Neurology</i> , 2016, 79, 929-939.	5.3	381
326	Suspected non-Alzheimer disease pathophysiology â€” concept and controversy. <i>Nature Reviews Neurology</i> , 2016, 12, 117-124.	10.1	230
327	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.8	1,318
328	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. <i>Alzheimer's and Dementia</i> , 2016, 12, 614-622.	0.8	42
329	Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring. <i>Neurobiology of Aging</i> , 2016, 40, 61-67.	3.1	11
330	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , The, 2016, 15, 455-532.	10.2	1,242
331	Different partial volume correction methods lead to different conclusions: An 18F-FDG-PET study of aging. <i>NeuroImage</i> , 2016, 132, 334-343.	4.2	216
332	CAPâ€”advancing the evaluation of preclinical Alzheimer disease treatments. <i>Nature Reviews Neurology</i> , 2016, 12, 56-61.	10.1	80
333	Biomarker validation of a decline in semantic processing in preclinical Alzheimerâ€™s disease.. <i>Neuropsychology</i> , 2016, 30, 624-630.	1.3	60
334	THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS. <i>journal of prevention of Alzheimer's disease</i> , The, 2016, 3, 1-5.	2.7	39
335	Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimerâ€™s Disease Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 249-260.	2.6	50
336	IC-P-084: Neurobiological correlates of anosognosia in mild cognitive impairment: A multimodal investigation using FDG-PET, PiB-PET, and volumetric MRI. , 2015, 11, P60-P60.		0
337	IC-P-125: Location, location, location: The distributed effects of amyloid on functional connectivity in the harvard aging brain study. , 2015, 11, P85-P86.		0
338	P4-083: Hippocampal metabolism is decreased in high-amyloid mild cognitive impairment but not in high-amyloid clinically normal elders. , 2015, 11, P802-P803.		0
339	P4-269: Relationships between baseline biomarkers and subsequent cognitive decline in cognitively unimpaired PSEN1 E280A mutation carriers from the colombian kindred with autosomal dominant Alzheimer's disease. , 2015, 11, P888-P888.		1
340	P3-217: Moderate caffeine consumption is associated with better memory scores in clinically normal older adults. , 2015, 11, P715-P716.		0
341	IC-P-071: Instrumental activities of daily living and functional connectivity in mild cognitive impairment. , 2015, 11, P53-P53.		0
342	IC-P-085: Regional Tau PET measures associated with memory performance in clinically normal older individuals. , 2015, 11, P60-P61.		0

#	ARTICLE	IF	CITATIONS
343	P1-319: Alzheimer's prevention registry: A shared resource to the scientific community to facilitate enrollment in studies. , 2015, 11, P479-P479.		1
344	O4-01-01: Regional Tau PET measures associated with memory performance in clinically normal older individuals. , 2015, 11, P265-P265.		1
345	Cardiorespiratory fitness is associated with white matter integrity in aging. Annals of Clinical and Translational Neurology, 2015, 2, 688-698.	3.7	47
346	Alzheimer's disease. Nature Reviews Disease Primers, 2015, 1, 15056.	30.5	1,210
347	Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2015, 46, 63-73.	2.6	87
348	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	2.6	317
349	IC-P-156: Baseline amyloid PET imaging, longitudinal amyloid accumulation, and Tau PET imaging in preclinical Alzheimer's disease. , 2015, 11, P105-P105.		0
350	P3-162: Instrumental activities of daily living and functional connectivity in mild cognitive impairment. , 2015, 11, P690-P691.		0
351	IC-P-162: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P109-P109.		2
352	F3-03-03: Disclosure of amyloid status in the a4 trial. , 2015, 11, P215-P215.		1
353	O4-01-03: Entorhinal tau deposition is associated with parietal association cortex hypometabolism in clinically normal older individuals. , 2015, 11, P266-P267.		0
354	The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 47, 421-432.	2.6	65
355	Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 46, 727-735.	2.6	44
356	Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. Neuropsychologia, 2015, 73, 169-175.	1.6	57
357	IC-P-068: The relationship of cognition, cognitive reserve, and in vivo tau and amyloid burden. , 2015, 11, P51-P51.		1
358	P3-104: Associations between subjective memory complaints and hippocampal volume in preclinical early-onset Alzheimer's disease. , 2015, 11, P660-P661.		0
359	F3-02-02: Snap in cognitively normal adults. , 2015, 11, P213-P213.		0
360	P2-141: Neurobiological correlates of anosognosia in mild cognitive impairment: A multi-modal investigation using FDG-PET, PiB-PET, and volumetric MRI. , 2015, 11, P540-P540.		0



#	ARTICLE	IF	CITATIONS
361	O3-09-06: Location, location, location: The distributed effects of amyloid on functional connectivity in the harvard aging brain study. , 2015, 11, P240-P240.		0
362	O5-01-01: Tau and amyloid deposits relate to distinctive cortical atrophy patterns in cognitively normal elderly. , 2015, 11, P311-P312.		0
363	P3-135: Clinical and neuroimaging predictors of psychological well-being as measured by the purpose in life scale in cognitively normal older individuals. , 2015, 11, P675-P676.		0
364	IC-P-153: Clinical and neuroimaging predictors of psychological well-being as measured by the purpose in life scale in cognitively normal older individuals. , 2015, 11, P102-P103.		0
365	O1-06-05: Baseline amyloid PET imaging, longitudinal amyloid accumulation, and Tau PET imaging in preclinical Alzheimer's disease. , 2015, 11, P139-P139.		0
366	O2-02-03: The relationship of cognition, cognitive reserve, and in vivo tau and amyloid burden. , 2015, 11, P175-P175.		0
367	O2-02-05: Differential declines in letter versus category fluency over 4 years in biomarker-defined preclinical Alzheimer's disease. , 2015, 11, P176-P177.		0
368	O4-01-04: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P267-P267.		1
369	O2-11-06: Reciprocal relations of loneliness and cognitive function in older u.s. adults. , 2015, 11, P201-P202.		0
370	Peripheral and central effects of $\beta$ -secretase inhibition by semagacestat in Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 36.	6.2	31
371	Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia. JAMA Neurology, 2015, 72, 446.	9.0	142
372	Amyloid- $\beta$ deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain, 2015, 138, 1023-1035.	7.6	207
373	Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology, 2015, 85, 48-55.	1.1	36
374	Subjective cognitive concerns, amyloid- $\beta$ , and neurodegeneration in clinically normal elderly. Neurology, 2015, 85, 56-62.	1.1	127
375	Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2015, 72, 912.	9.0	94
376	Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimer's Research and Therapy, 2015, 7, 26.	6.2	106
377	Predicting Reduction of Cerebrospinal Fluid $\beta$ -Amyloid 42 in Cognitively Healthy Controls. JAMA Neurology, 2015, 72, 554.	9.0	42
378	Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology, 2015, 84, 2153-2160.	1.1	120



#	ARTICLE	IF	CITATIONS
379	CD33 modulates TREM2: convergence of Alzheimer loci. <i>Nature Neuroscience</i> , 2015, 18, 1556-1558.	14.8	134
380	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2015, 85, 790-798.	1.1	27
381	Understanding Conflicting Neuropathological Findings in Patients Clinically Diagnosed as Having Alzheimer Dementia. <i>JAMA Neurology</i> , 2015, 72, 1106.	9.0	13
382	Amyloid- $\beta^{11}$ C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. <i>Neurology</i> , 2015, 85, 692-700.	1.1	136
383	Functional Connectivity in Multiple Cortical Networks Is Associated with Performance Across Cognitive Domains in Older Adults. <i>Brain Connectivity</i> , 2015, 5, 505-516.	1.7	69
384	Estimating Total Cerebral Microinfarct Burden From Diffusion-Weighted Imaging. <i>Stroke</i> , 2015, 46, 2129-2135.	2.0	52
385	Partial volume correction in quantitative amyloid imaging. <i>NeuroImage</i> , 2015, 107, 55-64.	4.2	188
386	Relationships between default-mode network connectivity, medial temporal lobe structure, and age-related memory deficits. <i>Neurobiology of Aging</i> , 2015, 36, 265-272.	3.1	86
387	The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease. <i>Journal of Prevention of Alzheimer's Disease</i> , 2015, 2, 242-253.	2.7	14
388	Regional Cortical Thinning and Cerebrospinal Biomarkers Predict Worsening Daily Functioning Across the Alzheimer's Disease Spectrum. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 719-728.	2.6	51
389	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
390	The A4 Study: Stopping AD Before Symptoms Begin?. <i>Science Translational Medicine</i> , 2014, 6, 228fs13.	12.4	588
391	Amyloid and <i>APOE <math>\epsilon</math>4</i> interact to influence short-term decline in preclinical Alzheimer disease. <i>Neurology</i> , 2014, 82, 1760-1767.	1.1	246
392	P3-266: NEUROPSYCHIATRIC SYMPTOMS AND FUNCTIONAL CONNECTIVITY IN MILD COGNITIVE IMPAIRMENT AND COGNITIVELY NORMAL ELDERLY. , 2014, 10, P729-P729.		0
393	Synergistic Effect of $\beta$ -Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals. <i>JAMA Neurology</i> , 2014, 71, 1379.	9.0	273
394	The Preclinical Alzheimer Cognitive Composite. <i>JAMA Neurology</i> , 2014, 71, 961.	9.0	548
395	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1111.	9.0	112
396	Amyloid Deposition Is Linked to Aberrant Entorhinal Activity among Cognitively Normal Older Adults. <i>Journal of Neuroscience</i> , 2014, 34, 5200-5210.	3.6	65

#	ARTICLE	IF	CITATIONS
397	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852.	0.8	1,863
398	Subjective Cognitive Concerns and Neuropsychiatric Predictors of Progression to the Early Clinical Stages of Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1642-1651.	1.2	167
399	Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2014, 370, 322-333.	27.0	1,613
400	Subjective cognitive concerns, episodic memory, and the <i>APOE</i> $\epsilon$ 4 allele. <i>Alzheimer's and Dementia</i> , 2014, 10, 752.	0.8	57
401	Task-Induced Brain Activity Patterns in Type 2 Diabetes: A Potential Biomarker for Cognitive Decline. <i>Diabetes</i> , 2014, 63, 3112-3119.	0.6	46
402	The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials. <i>Neuron</i> , 2014, 84, 608-622.	8.1	568
403	Template based rotation: A method for functional connectivity analysis with a priori templates. <i>NeuroImage</i> , 2014, 102, 620-636.	4.2	47
404	Regional Fluorodeoxyglucose Metabolism and Instrumental Activities of Daily Living across the Alzheimer's Disease Spectrum. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 291-300.	2.6	38
405	Symptom onset in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2014, 83, 253-260.	1.1	391
406	Regional Cortical Thinning Predicts Worsening Apathy and Hallucinations Across the Alzheimer Disease Spectrum. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1168-1179.	1.2	86
407	Flexible modulation of network connectivity related to cognition in Alzheimer's disease. <i>NeuroImage</i> , 2014, 100, 544-557.	4.2	18
408	The parahippocampal gyrus links the default-mode cortical network with the medial temporal lobe memory system. <i>Human Brain Mapping</i> , 2014, 35, 1061-1073.	3.6	236
409	P1-180: A NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING INSTRUMENT FOR EARLY ALZHEIMER'S DISEASE. , 2014, 10, P365-P365.		1
410	O3-07-02: WHITE MATTER BURDEN IN CLINICALLY NORMAL OLDER ADULTS MEDIATES THE RELATIONSHIP BETWEEN AMYLOID BURDEN AND MEMORY FREE RECALL BUT NOT CUED RECALL. , 2014, 10, P221-P222.		0
411	IC-P-087: DETECTING COGNITIVE PROFILES IN THE BIOMARKER STAGES OF PRECLINICAL AD. , 2014, 10, P49-P50.		1
412	IC-P-117: AMYLOID-B DEPOSITION IN MILD COGNITIVE IMPAIRMENT IS ASSOCIATED WITH HIPPOCAMPAL HYPERACTIVATION, ATROPHY, AND CLINICAL PROGRESSION. , 2014, 10, P65-P66.		1
413	THE A4 TRIAL: ANTI-AMYLOID TREATMENT OF ASYMPTOMATIC ALZHEIMER'S DISEASE. , 2014, 10, P246-P246.		3
414	P4-069: DEVELOPMENT OF A PROCESS TO DISCLOSE AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL OLDER ADULT RESEARCH PARTICIPANTS. , 2014, 10, P808-P808.		0

#	ARTICLE	IF	CITATIONS
415	DT-01-02: TEMPORAL NEOCORTICAL TAU DEPOSITION MEASURED WITH PET IS ASSOCIATED WITH LONGITUDINAL DECLINE IN MEMORY PERFORMANCE AMONG CLINICALLY NORMAL ELDERLY. , 2014, 10, P280-P280.		0
416	P2-154: SUBSYNDROMAL DEPRESSION AND ALZHEIMER'S DISEASE BIOMARKERS IN COGNITIVELY NORMAL ELDERLY. , 2014, 10, P527-P528.		0
417	IC-P-152: OLFACTORY IDENTIFICATION AND ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY NORMAL ELDERLY. , 2014, 10, P87-P87.		0
418	O3-10-06: AMYLOID- $\beta^2$ DEPOSITION IN MILD COGNITIVE IMPAIRMENT IS ASSOCIATED WITH HIPPOCAMPAL HYPERACTIVATION, ATROPHY, AND CLINICAL PROGRESSION. , 2014, 10, P230-P230.		0
419	P1-301: OLFACTORY IDENTIFICATION AND ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY NORMAL ELDERLY. , 2014, 10, P422-P422.		0
420	IC-02-01: GREATER SUBJECTIVE COGNITIVE CONCERNS CORRESPOND WITH ADVANCING STAGES OF PRECLINICAL AD. , 2014, 10, P4-P4.		0
421	F4-01-04: TAU PET USING F18-T807: INITIAL EXPERIENCE IN NORMAL ELDERLY AND AD DEMENTIA. , 2014, 10, P242-P242.		1
422	O4-12-04: DETECTING COGNITIVE PROFILES IN THE BIOMARKER STAGES OF PRECLINICAL AD. , 2014, 10, P276-P276.		0
423	P4-140: AMYLOID BURDEN-RELATED PERFORMANCE DIFFERENCES ON COGNITIVE AND FUNCTIONAL INSTRUMENTS ACROSS ALZHEIMER'S DISEASE PATHOPHYSIOLOGIC STAGES. , 2014, 10, P839-P839.		0
424	P2-246: GREATER SUBJECTIVE COGNITIVE CONCERNS CORRESPOND WITH ADVANCING STAGES OF PRECLINICAL AD. , 2014, 10, P566-P566.		1
425	Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review. Alzheimer's Research and Therapy, 2013, 5, 58.	6.2	146
426	Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiology of Aging, 2013, 34, 822-831.	3.1	118
427	The Ups and Downs of the Posteromedial Cortex: Age- and Amyloid-Related Functional Alterations of the Encoding/Retrieval Flip in Cognitively Normal Older Adults. Cerebral Cortex, 2013, 23, 1317-1328.	2.9	41
428	F5-03-03: Discussant. , 2013, 9, P826-P826.		0
429	O4-06-03: Genotype-phenotype studies examining the CD33 locus and amyloid biology. , 2013, 9, P692-P693.		0
430	IC-O1-02: Are early atrophy patterns in autosomal dominant familial Alzheimer's disease gene-dependent?. , 2013, 9, P3-P4.		0
431	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology, 2013, 81, 736-744.	1.1	174
432	Biomarkers of Alzheimer Disease. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 325-338.	0.8	34

#	ARTICLE	IF	CITATIONS
433	Preclinical Alzheimer disease—the challenges ahead. <i>Nature Reviews Neurology</i> , 2013, 9, 54-58.	10.1	232
434	Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. <i>Lancet Neurology</i> , The, 2012, 11, 1048-1056.	10.2	450
435	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 795-804.	27.0	3,005
436	O2-06-01: Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study. <i>Alzheimer's and Dementia</i> , 2012, 8, P244.	0.8	1
437	Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. <i>Neuropsychologia</i> , 2012, 50, 2880-2886.	1.6	379
438	To Sleep, Perchance to Delay Dementia. <i>Archives of Neurology</i> , 2012, 69, 118.	4.5	8
439	Dementia: new criteria but no new treatments. <i>Lancet Neurology</i> , The, 2012, 11, 4-5.	10.2	21
440	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. <i>Lancet Neurology</i> , The, 2012, 11, 241-249.	10.2	390
441	The potential of functional MRI as a biomarker in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2011, 32, S37-S43.	3.1	134
442	Testing the Right Target and Right Drug at the Right Stage. <i>Science Translational Medicine</i> , 2011, 3, 111cm33.	12.4	459
443	Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 280-292.	0.8	5,550
444	Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. , 2011, 7, 367-385.		531
445	O1-07-01: Alzheimer's-signature MRI biomarker predicts likelihood of Alzheimer's dementia in cognitively normal adults. , 2011, 7, S109-S109.		0
446	O2-01-01: Plasma and Cerebrospinal Fluid Markers in the DIAN Study of Autosomal-Dominant Alzheimer's Disease. , 2011, 7, S287-S287.		0
447	Amyloid- $\beta^2$ associated cortical thinning in clinically normal elderly. <i>Annals of Neurology</i> , 2011, 69, 1032-1042.	5.3	306
448	Functional Alterations in Memory Networks in Early Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2010, 12, 27-43.	3.4	497
449	Pro: Can biomarkers be gold standards in Alzheimer's disease?. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 17.	6.2	12
450	Large-Scale Functional Brain Network Abnormalities in Alzheimer's Disease: Insights from Functional Neuroimaging. <i>Behavioural Neurology</i> , 2009, 21, 63-75.	2.1	156

#	ARTICLE	IF	CITATIONS
451	Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2009, 29, 1860-1873.	3.6	2,576
452	Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia. <i>Neuron</i> , 2009, 63, 178-188.	8.1	899
453	Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden. <i>Journal of Neuroscience</i> , 2009, 29, 12686-12694.	3.6	530
454	Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 2181-2186.	7.1	344
455	Functional MRI Studies of Associative Encoding in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2007, 1097, 146-155.	3.8	210
456	Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. <i>Neurotherapeutics</i> , 2005, 2, 348-360.	4.4	1
457	Putting names to faces:. <i>NeuroImage</i> , 2003, 20, 1400-1410.	4.2	319
458	Functional MRI detection of pharmacologically induced memory impairment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 455-460.	7.1	198